Skip to main content


Figure 3 | BMC Medical Research Methodology

Figure 3

From: Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach

Figure 3

Evolution of the type I error of the Wald test according to the study design. Assuming ϵA = ϵB = 0.999, no limit of detection (“All data”, red line) or a limit of detection at 12 IU/mL (“ML”, blue line). N: number of patients per group of treatment; n: number of viral load measurements per patient; ntot: total numbers of observations per group of treatment.

Back to article page